Dario Gerace
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dario Gerace has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Rosetta Martiniello-Wilks
The School of Life Sciences and Centre for Health Technologies, Faculty of Science, University of Technology Sydney, Sydney, Australia
6 shared publications - Ann Margaret Simpson
School of Life Sciences, University of Technology Sydney, Ultimo, NSW, 2007, Australia
5 shared publications - Najah Therese Nassif
School of Life Sciences, University of Technology Sydney, Sydney 2007, Australia
3 shared publications Rosaline Habib
The School of Life Sciences and the Centre for Health Technologies, University of Technology Sydney, Sydney, Australia
2 shared publicationsRosetta Martiniello-Wilks
The School of Life Sciences and the Centre for Health Technologies, University of Technology Sydney, Sydney, Australia
2 shared publicationsA.M. Simpson
1 shared publication
Latest Publications
- Open Access
- 18 July 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (7) , e0220013
Luciferase-based reporting of suicide gene activity in murine mesenchymal stem cells
Due to their ease of isolation, gene modification and tumor-homing properties, mesenchymal stem cells (MSCs) are an attractive cellular vehicle for the delivery of toxic suicide genes to a variety of cancers in pre-clinical models. In addition, the incorporation of suicide genes in stem cell-derived cell replacement therapies improves their safety profile by permitting graft destruction in the event of unexpected tumorigeneses or unwanted differentiation. Due to the functional requirement of ATP for the Firefly luciferase gene Luc2 to produce light, luciferase-based reporting of cytotoxicity can be engineered into potential cell therapies. Consequently, we nucleofected mammalian expression plasmids containing both the Luc2 and the yeast fusion cytosine deaminase uracil phosphoribosyltransferase (CDUPRT) genes for expression in murine MSCs to assess luciferase as a reporter of suicide gene cytotoxicity, and MSC as vehicles of suicide gene therapy. In vitro bioluminescence imaging (BLI) showed that following the addition of the non-toxic prodrug fluorocytosine (5-FC), CDUPRT-expressing MSCs displayed enhanced cytotoxicity in comparison to Luc2 reporter MSC controls. This study demonstrates the utility of luciferase as a reporter of CDUPRT-mediated cytotoxicity in murine MSC using BLI.
- 18 July 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (7) , e0220013
Open AccessLuciferase-based reporting of suicide gene activity in murine mesenchymal stem cells
Due to their ease of isolation, gene modification and tumor-homing properties, mesenchymal stem cells (MSCs) are an attractive cellular vehicle for the delivery of toxic suicide genes to a variety of cancers in pre-clinical models. In addition, the incorporation of suicide genes in stem cell-derived cell replacement therapies improves their safety profile by permitting graft destruction in the event of unexpected tumorigeneses or unwanted differentiation. Due to the functional requirement of ATP for the Firefly luciferase gene Luc2 to produce light, luciferase-based reporting of cytotoxicity can be engineered into potential cell therapies. Consequently, we nucleofected mammalian expression plasmids containing both the Luc2 and the yeast fusion cytosine deaminase uracil phosphoribosyltransferase (CDUPRT) genes for expression in murine MSCs to assess luciferase as a reporter of suicide gene cytotoxicity, and MSC as vehicles of suicide gene therapy. In vitro bioluminescence imaging (BLI) showed that following the addition of the non-toxic prodrug fluorocytosine (5-FC), CDUPRT-expressing MSCs displayed enhanced cytotoxicity in comparison to Luc2 reporter MSC controls. This study demonstrates the utility of luciferase as a reporter of CDUPRT-mediated cytotoxicity in murine MSC using BLI.
- 5 July 2019
- Published by Springer Nature
- Vol. 2029, 197-214
High-Efficiency Lentiviral Gene Modification of Primary Murine Bone-Marrow Mesenchymal Stem Cells
Lentiviral vectors are the method of choice for stable gene modification of a variety of cell types. However, the efficiency with which they transduce target cells varies significantly, in particular their typically poor capacity to transduce primary stem cells. Here we describe the isolation and enrichment of murine bone-marrow mesenchymal stem cells (MSCs) via fluorescence-activated cell sorting (FACS); the cloning, production, and concentration of high-titer second generation lentiviral vectors via combined tangential flow filtration (TFF) and ultracentrifugation; and the subsequent high-efficiency gene modification of MSCs into insulin-producing cells via overexpression of the furin-cleavable human insulin (INS-FUR) gene.
- 5 July 2019
- Published by Springer Nature
- Vol. 2029, 197-214
High-Efficiency Lentiviral Gene Modification of Primary Murine Bone-Marrow Mesenchymal Stem Cells
Lentiviral vectors are the method of choice for stable gene modification of a variety of cell types. However, the efficiency with which they transduce target cells varies significantly, in particular their typically poor capacity to transduce primary stem cells. Here we describe the isolation and enrichment of murine bone-marrow mesenchymal stem cells (MSCs) via fluorescence-activated cell sorting (FACS); the cloning, production, and concentration of high-titer second generation lentiviral vectors via combined tangential flow filtration (TFF) and ultracentrifugation; and the subsequent high-efficiency gene modification of MSCs into insulin-producing cells via overexpression of the furin-cleavable human insulin (INS-FUR) gene.
- Open Access
- 10 March 2019
- Published by Wiley in Stem Cells International
- Vol. 2019, 1-15
Ex VivoExpansion of Murine MSC Impairs Transcription Factor-Induced Differentiation into Pancreaticβ-Cells
Combinatorial gene and cell therapy as a means of generating surrogateβ-cells has been investigated for the treatment of type 1 diabetes (T1D) for a number of years with varying success. One of the limitations of current cell therapies for T1D is the inability to generate sufficient quantities of functional transplantable insulin-producing cells. Due to their impressive immunomodulatory properties, in addition to their ease of expansion and genetic modificationex vivo, mesenchymal stem cells (MSCs) are an attractive alternative source of adult stem cells for regenerative medicine. To overcome the aforementioned limitation of current therapies, we assessed the utility ofex vivoexpanded bone marrow-derived murine MSCs for their persistence in immune-competent and immune-deficient animal models and their ability to differentiate into surrogateβ-cells. CD45-/Ly6+murine MSCs were isolated from the bone marrow of nonobese diabetic (NOD) mice and nucleofected to express the bioluminescent protein,Firefly luciferase (Luc2). The persistence of a subcutaneous (s.c.) transplant ofLuc2-expressing MSCs was assessed in immune-competent (NOD) () and immune-deficient (NOD/Scid) () animal models of diabetes.Luc2-expressing MSCs persisted for 2 and 12 weeks, respectively, in NOD and NOD/Scidmice.Ex vivoexpanded MSCs were transduced with the HMD lentiviral vector (MOI = 10) to express furin-cleavable human insulin (INS-FUR) and murineNeuroD1andPdx1. This was followed by the characterization of pancreatic transdifferentiation via reverse transcriptase polymerase chain reaction (RT-PCR) and static and glucose-stimulated insulin secretion (GSIS).INS-FUR-expressing MSCs were assessed for their ability to reverse diabetes after transplantation into streptozotocin- (STZ-) diabetic NOD/Scidmice ().Transduced MSCs did not undergo pancreatic transdifferentiation, as determined by RT-PCR analyses, lacked glucose responsiveness, and upon transplantation did not reverse diabetes. The data suggest thatex vivoexpanded MSCs lose their multipotent differentiation potential and may be more useful as gene therapy targets prior to expansion.- 10 March 2019
- Published by Wiley in Stem Cells International
- Vol. 2019, 1-15
Open AccessEx VivoExpansion of Murine MSC Impairs Transcription Factor-Induced Differentiation into Pancreaticβ-Cells
Combinatorial gene and cell therapy as a means of generating surrogateβ-cells has been investigated for the treatment of type 1 diabetes (T1D) for a number of years with varying success. One of the limitations of current cell therapies for T1D is the inability to generate sufficient quantities of functional transplantable insulin-producing cells. Due to their impressive immunomodulatory properties, in addition to their ease of expansion and genetic modificationex vivo, mesenchymal stem cells (MSCs) are an attractive alternative source of adult stem cells for regenerative medicine. To overcome the aforementioned limitation of current therapies, we assessed the utility ofex vivoexpanded bone marrow-derived murine MSCs for their persistence in immune-competent and immune-deficient animal models and their ability to differentiate into surrogateβ-cells. CD45-/Ly6+murine MSCs were isolated from the bone marrow of nonobese diabetic (NOD) mice and nucleofected to express the bioluminescent protein,Firefly luciferase (Luc2). The persistence of a subcutaneous (s.c.) transplant ofLuc2-expressing MSCs was assessed in immune-competent (NOD) () and immune-deficient (NOD/Scid) () animal models of diabetes.Luc2-expressing MSCs persisted for 2 and 12 weeks, respectively, in NOD and NOD/Scidmice.Ex vivoexpanded MSCs were transduced with the HMD lentiviral vector (MOI = 10) to express furin-cleavable human insulin (INS-FUR) and murineNeuroD1andPdx1. This was followed by the characterization of pancreatic transdifferentiation via reverse transcriptase polymerase chain reaction (RT-PCR) and static and glucose-stimulated insulin secretion (GSIS).INS-FUR-expressing MSCs were assessed for their ability to reverse diabetes after transplantation into streptozotocin- (STZ-) diabetic NOD/Scidmice ().Transduced MSCs did not undergo pancreatic transdifferentiation, as determined by RT-PCR analyses, lacked glucose responsiveness, and upon transplantation did not reverse diabetes. The data suggest thatex vivoexpanded MSCs lose their multipotent differentiation potential and may be more useful as gene therapy targets prior to expansion. - Open Access
- 9 March 2017
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 8 (1) , 1-10
CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success?
Due to their ease of isolation, differentiation capabilities, and immunomodulatory properties, the therapeutic potential of mesenchymal stem cells (MSCs) has been assessed in numerous pre-clinical and clinical settings. Currently, whole pancreas or islet transplantation is the only cure for people with type 1 diabetes (T1D) and, due to the autoimmune nature of the disease, MSCs have been utilised either natively or transdifferentiated into insulin-producing cells (IPCs) as an alternative treatment. However, the initial success in pre-clinical animal models has not translated into successful clinical outcomes. Thus, this review will summarise the current state of MSC-derived therapies for the treatment of T1D in both the pre-clinical and clinical setting, in particular their use as an immunomodulatory therapy and targets for the generation of IPCs via gene modification. In this review, we highlight the limitations of current clinical trials of MSCs for the treatment of T1D, and suggest the novel clustered regularly interspaced short palindromic repeat (CRISPR) gene-editing technology and improved clinical trial design as strategies to translate pre-clinical success to the clinical setting.
- 9 March 2017
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 8 (1) , 1-10
Open AccessCRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success?
Due to their ease of isolation, differentiation capabilities, and immunomodulatory properties, the therapeutic potential of mesenchymal stem cells (MSCs) has been assessed in numerous pre-clinical and clinical settings. Currently, whole pancreas or islet transplantation is the only cure for people with type 1 diabetes (T1D) and, due to the autoimmune nature of the disease, MSCs have been utilised either natively or transdifferentiated into insulin-producing cells (IPCs) as an alternative treatment. However, the initial success in pre-clinical animal models has not translated into successful clinical outcomes. Thus, this review will summarise the current state of MSC-derived therapies for the treatment of T1D in both the pre-clinical and clinical setting, in particular their use as an immunomodulatory therapy and targets for the generation of IPCs via gene modification. In this review, we highlight the limitations of current clinical trials of MSCs for the treatment of T1D, and suggest the novel clustered regularly interspaced short palindromic repeat (CRISPR) gene-editing technology and improved clinical trial design as strategies to translate pre-clinical success to the clinical setting.
- Open Access
- 1 May 2015
- Published by Elsevier in Molecular Therapy
- Vol. 23, S101
257. Persistence of Luciferase Expressing Bone Marrow-Derived Mesenchymal Stem Cells (BMSCs) in Non-Obese Diabetic (NOD) and NOD/Scid Mice
- 1 May 2015
- Published by Elsevier in Molecular Therapy
- Vol. 23, S101
Open Access257. Persistence of Luciferase Expressing Bone Marrow-Derived Mesenchymal Stem Cells (BMSCs) in Non-Obese Diabetic (NOD) and NOD/Scid Mice
- Open Access
- 1 January 2015
- Published by Taylor & Francis in Research and Reports in Endocrine Disorders
- p. 15
Diabetes reversal via gene transfer: building on successes in animal models
Diabetes reversal via gene transfer: building on successes in animal models Dario Gerace,1,* Rosetta Martiniello-Wilks,1,2,* Ann M Simpson1 1School of Medical and Molecular Biosciences, Centre for Health Technologies, 2Translational Cancer Research Group, University of Technology Sydney, Sydney, NSW, Australia *These authors contributed equally to this work Type 1 diabetes (T1D) is caused by the autoimmune destruction of the insulin-producing pancreatic β-cells. People with T1D manage their hyperglycemia using daily insulin injections; however, this does not prevent the development of long-term diabetic complications such as retinopathy, nephropathy, neuropathy, and various macrovascular disorders. Currently, the only "cure" for T1D is pancreas transplantation or islet-cell transplantation; however, this is hampered by the limited number of donors and the requirement for life-long immunosuppression. As a result, the need for alternative therapies is vital. One of the strategies employed to correct T1D is the use of gene transfer to generate the production of an “artificial” β-cell that is capable of secreting insulin in response to fluctuating glucose concentrations that normally occurs in people without T1D. The treatment of many diseases using cell and gene therapy is generating significant attention in the T1D research community; however, for a cell therapy to enter clinical trials, success and safety must first be shown in an appropriate animal model. Animal models have been used in diabetes research for over a century, have improved our understanding of the pathophysiology of diabetes, and have led to the discovery of useful drugs for the treatment of the disease. Currently, the nonobese diabetic mouse is the animal model of choice for the study of T1D as it most closely reflects disease development in humans. The aim of this review is to evaluate the success of cell and gene therapy to reverse T1D in animal models for future clinical application. Keywords: β-cell transcription factors, animal models, gene therapy, insulin
- 1 January 2015
- Published by Taylor & Francis in Research and Reports in Endocrine Disorders
- p. 15
Open AccessDiabetes reversal via gene transfer: building on successes in animal models
Diabetes reversal via gene transfer: building on successes in animal models Dario Gerace,1,* Rosetta Martiniello-Wilks,1,2,* Ann M Simpson1 1School of Medical and Molecular Biosciences, Centre for Health Technologies, 2Translational Cancer Research Group, University of Technology Sydney, Sydney, NSW, Australia *These authors contributed equally to this work Type 1 diabetes (T1D) is caused by the autoimmune destruction of the insulin-producing pancreatic β-cells. People with T1D manage their hyperglycemia using daily insulin injections; however, this does not prevent the development of long-term diabetic complications such as retinopathy, nephropathy, neuropathy, and various macrovascular disorders. Currently, the only "cure" for T1D is pancreas transplantation or islet-cell transplantation; however, this is hampered by the limited number of donors and the requirement for life-long immunosuppression. As a result, the need for alternative therapies is vital. One of the strategies employed to correct T1D is the use of gene transfer to generate the production of an “artificial” β-cell that is capable of secreting insulin in response to fluctuating glucose concentrations that normally occurs in people without T1D. The treatment of many diseases using cell and gene therapy is generating significant attention in the T1D research community; however, for a cell therapy to enter clinical trials, success and safety must first be shown in an appropriate animal model. Animal models have been used in diabetes research for over a century, have improved our understanding of the pathophysiology of diabetes, and have led to the discovery of useful drugs for the treatment of the disease. Currently, the nonobese diabetic mouse is the animal model of choice for the study of T1D as it most closely reflects disease development in humans. The aim of this review is to evaluate the success of cell and gene therapy to reverse T1D in animal models for future clinical application. Keywords: β-cell transcription factors, animal models, gene therapy, insulin
- 23 October 2014
- Published by Springer Nature in Gene Therapy
- Vol. 22 (1) , 1-8
The use of β-cell transcription factors in engineering artificial β cells from non-pancreatic tissue
Type 1 diabetes results from the autoimmune destruction of the insulin-producing pancreatic beta (beta) cells. Patients with type 1 diabetes control their blood glucose levels using several daily injections of exogenous insulin; however, this does not eliminate the long-term complications of hyperglycaemia. Currently, the only clinically viable treatments for type 1 diabetes are whole pancreas and islet transplantation. As a result, there is an urgent need to develop alternative therapies. Recently, cell and gene therapy have shown promise as a potential cure for type 1 diabetes through the genetic engineering of 'artificial' beta cells to regulate blood glucose levels without adverse side effects and the need for immunosuppression. This review compares putative target cells and the use of pancreatic transcription factors for gene modification, with the ultimate goal of engineering a glucose-responsive 'artificial' beta cell that mimics the function of pancreatic beta cells, while avoiding autoimmune destruction.
- 23 October 2014
- Published by Springer Nature in Gene Therapy
- Vol. 22 (1) , 1-8
The use of β-cell transcription factors in engineering artificial β cells from non-pancreatic tissue
Type 1 diabetes results from the autoimmune destruction of the insulin-producing pancreatic beta (beta) cells. Patients with type 1 diabetes control their blood glucose levels using several daily injections of exogenous insulin; however, this does not eliminate the long-term complications of hyperglycaemia. Currently, the only clinically viable treatments for type 1 diabetes are whole pancreas and islet transplantation. As a result, there is an urgent need to develop alternative therapies. Recently, cell and gene therapy have shown promise as a potential cure for type 1 diabetes through the genetic engineering of 'artificial' beta cells to regulate blood glucose levels without adverse side effects and the need for immunosuppression. This review compares putative target cells and the use of pancreatic transcription factors for gene modification, with the ultimate goal of engineering a glucose-responsive 'artificial' beta cell that mimics the function of pancreatic beta cells, while avoiding autoimmune destruction.
- 1 June 2013
- Published by Elsevier in Transplantation Proceedings
- Vol. 45 (5) , 1869-1874
Pancreatic Transdifferentiation in Porcine Liver Following Lentiviral Delivery of Human Furin–Cleavable Insulin
- 1 June 2013
- Published by Elsevier in Transplantation Proceedings
- Vol. 45 (5) , 1869-1874
Pancreatic Transdifferentiation in Porcine Liver Following Lentiviral Delivery of Human Furin–Cleavable Insulin